RORgamma Modulators 2016: A Comparative Analysis of the Landscape of RORgamma Antagonists and Agonists; New Report Launched
Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but "difficult-to-drug" target. More than 30 companies are active in drug discovery and development. Technology companies with expertise in discovery of drugs targeting nuclear hormone receptors are preferred partners of Big Pharma and Biotech companies if they have identified novel scaffolds of RORgamma antagonists. More than ten such technology-pharma partnerships have been founded and already lead to first successes. Three RORgamma antagonists (inverse agonists) are already in clinical development and...
View full press release